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Aim of the study
The aims of the study were:
1. To evaluate correlation between the level of Se and
occurrence of lung, laryngeal, colorectal and prostate
cancers (retrospective study)
2. To determine risk of breast cancer depending on Se
level (prospective study)
Material and methods
The study was performed in five groups. For four of them
(cancers of the lung, larynx, colon, prostate) and matched
healthy controls serum was collected before treatment but
during diagnosis. Whereas for breast cancer group serum
was collected 1 - 2 years before tumor diagnosis. Cases
and controls in each study groups were matched for year
of birth (+/-3 years), number and location of cancer
among Iº relatives, smoking - the number of pack years
(+/- 10%) and adnexectomy (only for breast cancer group).
Se level in serum was determined in all individuals by
inductively coupled plasma mass spectrometry (ICP-MS)
using Elan DRC-e ICP-Mass Spectrometer, Perkin Elmer.
For selenium measurements strong quality control criteria
was applied: reference material (SeronoformTM) was mea-
sured every four samples, cases and controls samples were
tested alternately, correction value: +/- 5%.
After obtaining results from mass spectrometry, indivi-
duals in each group were divided into four categories
(quartiles). Comparison of number of cases and controls
was performed in each quartile. To evaluate the occur-
rence of cancers, individuals with the lowest selenium
level (quartile) was taken as reference category.
Results
It was observed that detailed analysis of selenium concen-
trations showed that in groups of lung, laryngeal, colorec-
tal and prostate cancers, and low Se level in serum is
associated with an increase of cancers frequency. It was
also observed that when Se level is higher the number of
cancers decreases. In contrast, selenium level >100 μg/l in
serum was associated with increased incidence of breast
cancer (OR 5.89; p = 0.0004; CI = 2.19 - 15.84).
Conclusions
1. low level of selenium may be diagnostic marker for
selection of people to:
- CT for lung cancer cases
- laryngeal examination for larynx cancer cases
- colonoscopy- colon cancer cases
- prostate examination (PSA, biopsy) - prostate
cancer cases
2. Se level above 100 μg/l is a marker of high risk of
breast cancer
Authors’ details
1Department of Genetics and Pathology, International Hereditary Cancer
Center, Pomeranian Medical University, Szczecin, Poland. 2Read - Gene, S.A.,
Grzepnica, Poland.
Published: 26 November 2015
doi:10.1186/1897-4287-13-S2-A3
Cite this article as: Jaworska-Bieniek et al.: Selenium as diagnostic marker
of cancers. Hereditary Cancer in Clinical Practice 2015 13(Suppl 2):A3.
* Correspondence: ka_jawoska@wp.pl
1Department of Genetics and Pathology, International Hereditary Cancer
Center, Pomeranian Medical University, Szczecin, Poland
Full list of author information is available at the end of the article
Jaworska-Bieniek et al. Hereditary Cancer in Clinical Practice 2015, 13(Suppl 2):A3
http://www.hccpjournal.com/content/13/S2/A3
© 2015 Jaworska-Bieniek et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
